Market Research Logo

Asia Pacific Epigenomics Market 2018-2026

Asia Pacific Epigenomics Market 2018-2026

KEY FINDINGS

Driven by the high incidence of cancer, the rise in healthcare expenditure, and growing investments and funds for emerging applications, the Asia-Pacific epigenomics market is anticipated to register a CAGR of 20.57% for the forecast period of 2018-2026.

MARKET INSIGHTS

South Korea is anticipated to register the highest CAGR by the end of 2026. The Korean Ministry of Health and Welfare provides mandatory universal healthcare to its residents under the single-payer National Health Insurance System. Also, the elderly population is considerably high in this region. Together, these factors have increased the demand for the epigenomics market in the region. The DNA methylation technology has held a considerable share in this market.

COMPETITIVE INSIGHTS

Epigenomics Ag, Rubicon Genomics, Affymetrix, Abbott Laboratories, Novartis Pharma Ag, Johnson & Johnson, Glaxosmithkline, Astellas Pharmaceuticals, Agilent Technologies, Illumina Inc, Merck Sharp & Dohme, Roche Holding Ag, Laboratory Corp Of America Holdings, Bayer Ag, Epigentek, Orchid Chemicals & Pharmaceuticals Limited, and Celgene Corp are few of the noted companies in the epigenomics market.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top-down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1 Asia Pacific Is Anticipated To Be The Most Dynamic Regional Market
3.2.2 Reagents Forms A Major Part Of Epigenomic Market By Product
3.2.3 Epigenetics Diagnosis Is A Major Part Of Epigenomic Market, And Personalized Medicines Is Showing A Dynamic Growth
3.2.4 Oncology Is The Primary Application While Non-oncology Is Showing A Better Growth
4. Market Dynamics
4.1. Market Definition & Scope
4.2. Market Drivers
4.2.1. Advancement In The Prevalence Of Cancer And Other Chronic Diseases
4.2.2. Rise In The Ageing Population
4.2.3. Decline In The Sequencing Costs And Time
4.2.4. Escalation In Funding For Research & Development
4.2.5. Need For Better Cancer Therapies
4.2.6. Growth In Personalized Medicine
4.2.7. Increasing Importance Of Epigenetic Technology
4.3. Market Restraints
4.3.1 Inefficiency In Identification And Validation Of Biomarker
4.3.2 Presence Of Complex Regulatory Framework
4.3.3 Lack Of Reimbursement Provision In Insurance For Epigenomic
4.4. Market Opportunities
4.4.1 Increasing Awareness About Epigenomic
4.4.2 Advancement Of Potential In Emerging Markets
4.4.3 Expanding Applications Of Epigenetics In Personalized Medicine And Targeted Therapy
4.4.4 Use Of Epigenomic In Non-oncology Applications
4.5. Market Challenges
4.5.1 Scarcity Of Trained Professionals
4.5.2 High Cost Of Instruments And Consumables
5. Market By Product
5.1. Reagents
5.2. Kits
5.3. Instruments
5.4. Enzymes
5.5. Services
6. Market By Technology
6.1. Dna Methylation
6.2. Histone Methylation & Acetylation
6.3. Microrna Modification
7. Market By Application
7.1. Oncology
7.1.1. Dna Methyltransferase Inhibitors
7.1.2. Histone Deacetylase Inhibitors
7.2. Non-oncology
8. Market By Application Area
8.1. Diagnosis
8.2. Drug Discovery
8.3. Therapy Optimization
8.4. Prognosis
9. Market By Segment
9.1. Epigenetic Diagnosis
9.1.1. Cancer
9.1.2. Neuro
9.1.2.1. Mental Retardation
9.1.2.2. Alzheimer’s Disease
9.1.2.3. Depression
9.1.2.4. Other
9.1.3. Cardiovascular
9.1.3.1. Vascular Disease
9.1.3.2. Heart Failure
9.1.3.3. Others
9.1.4. Inflammatory & Autoimmune Disease
9.1.4.1. Rheumatoid Arthritis
9.1.4.2. Diabetes
9.1.4.3. Lupus
9.1.4.4. Multiple Sclerosis
9.1.4.5. Inflammatory Bowel Diseases
9.1.5. R&D
9.1.5.1. Dna Methylation In Cancer Detection
9.1.5.2. Identification Of Epigenetic Biomarkers For Diagnosis And Prediction
9.1.5.3. Mechanisms Of Epigenetic Gene Silencing
9.2. Personalized Medicine
9.2.1. Cancer Treatment
9.2.1.1. Lung Cancer
9.2.1.2. Solid Cancers
9.2.1.3. Gastric Cancer
9.2.1.4. Haematological Cancers
9.2.1.5. Others
9.2.2. Neurological Disorders
9.2.2.1. Mental Retardation
9.2.2.2. Huntington’s Disease
9.2.2.3. Parkinson’s Disease
9.2.2.4. Alzheimer’s Disease
9.2.2.5. Depression
9.2.3. Cvd
9.2.4. Others
9.2.4.1. Rheumatoid Arthritis
9.2.4.2. Diabetes
9.2.4.3. Myelodysplastic Syndromes
9.2.4.4. Multiple Sclerosis
9.2.4.5. Obesity
9.2.4.6. Inflammatory Bowel Diseases
9.2.4.7. Lupus
9.2.4.8. Other
9.3. Epigenetic Therapies
9.4. Biomarkers
9.4.1. Dna Methylation For Cancer Detection
9.4.2. Histonic Modification As Biomarker In Cancer Detection
9.4.2.1. Histone Methylation
9.4.2.2. Histone Acetylation
9.4.3. Noncoding Rnas
9.4.4. Mirnas
9.4.5. Chromatin Remodeling
10. Key Analytics
10.1. Porter’s Five Force Model
10.1.1. Threat Of New Entrants
10.1.2. Threat Of Substitute
10.1.3. Bargaining Power Of Suppliers
10.1.4. Bargaining Power Of Buyers
10.1.5. Threat Of Competitive Rivalry
10.2. Opportunity Matrix
10.3. Vendor Landscape
11. Geographical Analysis
11.1. Asia Pacific
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. South Korea
11.1.5. Rest Of Asia Pacific
12. Company Profiles
12.1. Abbott Laboratories
12.2. Affymetrix
12.3. Agilent Technologies
12.4. Astellas Pharmaceuticals
12.5. Bayer Ag
12.6. Bio Vision
12.7. Celgene Corp.
12.8. Epigenomics Ag
12.9. Glaxosmithkline
12.10. Illumina Inc.
12.11. Johnson & Johnson
12.12. Merck Sharp & Dohme
12.13. Naturewise Biotech & Medicals Corp.
12.14. Novartis Pharma Ag
12.15. Orchid Chemicals & Pharmaceuticals Limited
12.16. Tbg Diagnostics Limited
12.17. Rubicon Genomics
12.18. Roche Holding Ag
Table List
Table 1 Asia Pacific Epigenomic Market, By Country, 2018-2026, (In $ Ten Thousand)
Table 2 Asia Pacific Epigenomic Market, By Product, 2018-2026, (In $ Ten Thousand)
Table 3 Asia Pacific Epigenomic Market, By Technology, 2018-2026, (In $ Ten Thousand)
Table 4 Asia Pacific Epigenomic Market, By Application, 2018-2026, (In $ Ten Thousand)
Table 5 Asia Pacific Epigenomic Market, By Application Area, 2018-2026, (In $ Ten Thousand)
Table 6 Asia Pacific Epigenomic Market, By Segment, 2018-2026, (In $ Ten Thousand)
Table 7 Asia Pacific Epigenomic Market, By Epigenetic Diagnosis, 2018-2026 (In $ Ten Thousand)
Table 8 Asia Pacific Epigenetic Diagnosis Market, By Neuro, 2018-2026, (In $ Ten Thousand)
Table 9 Asia Pacific Epigenetic Diagnosis Market, By Cardiovascular, 2018-2026, (In $ Ten Thousand)
Table 10 Asia Pacific Epigenetic Diagnosis Market, By Inflammatory & Autoimmune Disease, 2018-2026, (In $ Ten Thousand)
Table 11 Asia Pacific Epigenetic Diagnosis Market, By R&D, 2018-2026, (In $ Ten Thousand)
Table 12 Asia Pacific Epigenomic Market, By Personalized Medicine, 2018-2026, (In $ Ten Thousand)
Table 13 Asia Pacific Personalized Medicine Market, By Cancer Treatment, 2018-2026, (In $ Ten Thousand)
Table 14 Asia Pacific Personalized Medicine Market, By Neurological Disorders, 2018-2026 (In $ Ten Thousand)
Table 15 Asia Pacific Personalized Medicine Market, By Others, 2018-2026 (In $ Ten Thousand)
Table 16 Asia Pacific Epigenomics Market, By Biomarkers, 2018-2026 (In $ Ten Thousand)
Table 17 Opportunity Matrix
Table 18 Vendor Landscape
Table 19 Asia Pacific Epigenomic Market, By Country, 2018-2026 (In $ Ten Thousand)
Figure List
Figure 1 Asia Pacific Epigenomic Market Share, By Segment 2017 & 2026 (%)
Figure 2 Asia Pacific Revenue Estimation ($ Ten Thousand)
Figure 3 Reagents Estimated Revenue ($ten Thousand)
Figure 4 Epigenetic Diagnosis Estimated Revenue ($ Ten Thousand)
Figure 5 Personalized Medicines Estimated Revenue ($ Ten Thousand)
Figure 6 Oncology Revenue Estimation ($ Ten Thousand)
Figure 7 Non-oncology Revenue Estimation ($ Ten Thousand)
Figure 8 Asia Pacific Epigenomic Market, By Reagents, 2018-2026, (In $ Ten Thousand)
Figure 9 Asia Pacific Epigenomic Market, By Kits, 2018-2026, (In $ Ten Thousand)
Figure 10 Asia Pacific Epigenomic Market, By Instruments, 2018-2026, (In $ Ten Thousand)
Figure 11 Asia Pacific Epigenomic Market, By Enzymes, 2018-2026, (In $ Ten Thousand)
Figure 12 Asia Pacific Epigenomic Market, By Services, 2018-2026, (In $ Ten Thousand)
Figure 13 Asia Pacific Epigenomic Market, By Dna Methylation, 2018-2026, (In $ Ten Thousand)
Figure 14 Asia Pacific Epigenomic Market, By Histone Methylation And Acetylation, 2018-2026, (In $ Ten Thousand)
Figure 15 Asia Pacific Epigenomic Market, By Micro-rna Modification, 2018-2026, (In $ Ten Thousand)
Figure 16 Asia Pacific Epigenomic Market, By Oncology, 2018-2026, (In $ Ten Thousand)
Figure 17 Asia Pacific Epigenomic Market, By Dna Methyltransferase Inhibitors, 2018-2026, (In $ Ten Thousand)
Figure 18 Asia Pacific Epigenomic Market, By Histone Deacetylase Inhibitors, 2018-2026, (In $ Ten Thousand)
Figure 19 Asia Pacific Epigenomic Market, By Non-oncology, 2018-2026, (In $ Ten Thousand)
Figure 20 Asia Pacific Epigenomic Market, By Diagnosis, 2018-2026, (In $ Ten Thousand)
Figure 21 Asia Pacific Epigenomic Market, By Drug Discovery, 2018-2026, (In $ Ten Thousand)
Figure 22 Asia Pacific Epigenomic Market, By Therapy Optimization, 2018-2026, (In $ Ten Thousand)
Figure 23 Asia Pacific Epigenomic Market, By Prognosis, 2018-2026, (In $ Ten Thousand)
Figure 24 Asia Pacific Epigenomic Market, By Epigenetic Diagnosis, 2018-2026, (In $ Ten Thousand)
Figure 25 Asia Pacific Epigenomic Market, By Epigenetic Diagnosis-cancer, 2018-2026, (In $ Ten Thousand)
Figure 26 Asia Pacific Epigenomic Market, By Neuro-mental Retardation, 2018-2026, (In $ Ten Thousand)
Figure 29 Asia Pacific Epigenomic Market, By Neuro- Alzheimer’s Disease, 2018-2026, (In $ Ten Thousand)
Figure 30 Asia Pacific Epigenomic Market, By Neuro- Depression, 2018-2 026, (In $ Ten Thousand)
Figure 31 Asia Pacific Epigenomic Market, By Neuro- Other, 2018-2026, (In $ Ten Thousand)
Figure 32 Asia Pacific Epigenomic Market, By Cardiovascular-vascular Disease, 2018-2026, (In $ Ten Thousand)
Figure 33 Asia Pacific Epigenomic Market, By Cardiovascular- Heart Failure, 2018-2026, (In $ Ten Thousand)
Figure 34 Asia Pacific Epigenomic Market, By Cardiovascular- Others, 2018-2026, (In $ Ten Thousand)
Figure 35 Asia Pacific Epigenomic Market, By Rheumatoid Arthritis, 2018-2026, (In $ Ten Thousand)
Figure 36 Asia Pacific Epigenomic Market, By Diabetes, 2018-2026, (In $ Ten Thousand)
Figure 37 Asia Pacific Epigenomic Market, By Lupus, 2018-2026, (In $ Ten Thousand)
Figure 38 Asia Pacific Epigenomic Market, By Multiple Sclerosis, 2018-2026, (In $ Ten Thousand)
Figure 39 Asia Pacific Epigenomic Market, By Inflammatory Bowel Diseases, 2018-2026, (In $ Ten Thousand)
Figure 40 Asia Pacific Epigenomic Market, By Dna Methylation In Cancer Detection, 2018-2026, (In $ Ten Thousand)
Figure 41 Asia Pacific Epigenomic Market, By Identification Of Epigenetic Biomarkers For Diagnosis And Prediction, 2018-2026, (In $ Ten Thousand)
Figure 42 Asia Pacific Epigenomic Market, By Mechanisms Of Epigenetic Gene Silencing, 2018-2026, (In $ Ten Thousand)
Figure 43 Asia Pacific Epigenomic Market, By Cancer Treatment, 2018-2026, (In $ Ten Thousand)
Figure 44 Asia Pacific Epigenomic Market, By Lung Cancer, 2018-2026, (In $ Ten Thousand)
Figure 45 Asia Pacific Epigenomic Market, By Solid Cancers, 2018-2026, (In $ Ten Thousand)
Figure 46 Asia Pacific Epigenomic Market, By Gastric Cancer, 2018-2026, (In $ Ten Thousand)
Figure 47 Asia Pacific Epigenomic Market, By Hematological Cancers, 2018-2026, (In $ Ten Thousand)
Figure 48 Asia Pacific Epigenomic Market, By Others, 2018-2026, (In $ Ten Thousand)
Figure 49 Asia Pacific Epigenomic Market, By Mental Retardation, 2018-2026, (In $ Ten Thousand)
Figure 50 Asia Pacific Epigenomic Market, By Huntington’s Disease, 2018-2026, (In $ Ten Thousand)
Figure 51 Asia Pacific Epigenomic Market, By Parkinson’s Disease, 2018-2026, (In $ Ten Thousand)
Figure 52 Asia Pacific Epigenomic Market, By Alzheimer’s Disease, 2018-2026, (In $ Ten Thousand)
Figure 53 Asia Pacific Epigenomic Market, By Depression, 2018-2026, (In $ Ten Thousand)
Figure 54 Asia Pacific Epigenomic Market, By Cvd, 2018-2026, (In $ Ten Thousand)
Figure 55 Asia Pacific Epigenomic Market, By Rheumatoid Arthritis, 2018-2026, (In $ Ten Thousand)
Figure 56 Asia Pacific Epigenomic Market, By Diabetes, 2018-2026, (In $ Ten Thousand)
Figure 57 Asia Pacific Epigenomic Market, By Myelodysplastic Syndromes, 2018-2026, (In $ Ten Thousand)
Figure 58 Asia Pacific Epigenomic Market, By Multiple Sclerosis, 2018-2026, (In $ Ten Thousand)
Figure 59 Asia Pacific Epigenomic Market, By Obesity, 2018-2026, (In $ Ten Thousand)
Figure 60 Asia Pacific Epigenomic Market, By Inflammatory Bowel Diseases, 2018-2026, (In $ Ten Thousand)
Figure 61 Asia Pacific Epigenomic Market, By Lupus, 2018-2026, (In $ Ten Thousand)
Figure 62 Asia Pacific Epigenomic Market, By Other, 2018-2026, (In $ Ten Thousand)
Figure 63 Asia Pacific Epigenomic Market, By Epigenetic Therapies, 2018-2026, (In $ Ten Thousand)
Figure 64 Asia Pacific Epigenomic Market, By Biomarkers, 2018-2026, (In $ Ten Thousand)
Figure 65 Asia Pacific Epigenomic Market, By Dna Methylation, 2018-2026, (In $ Ten Thousand)
Figure 66 Asia Pacific Epigenomic Market, By Histonic Modification, 2018-2026, (In $ Ten Thousand)
Figure 67 Asia Pacific Epigenomic Market, By Histone Methylation, 2018-2026, (In $ Ten Thousand)
Figure 68 Asia Pacific Epigenomic Market, By Histone Acetylation, 2018-2026, (In $ Ten Thousand)
Figure 69 Asia Pacific Epigenomic Market, By Noncoding Rnas, 2018-2026, (In $ Ten Thousand)
Figure 70 Asia Pacific Epigenomic Market, By Mirnas, 20 18-2026, (In $ Ten Thousand)
Figure 71 Asia Pacific Epigenomic Market, By Chromatin Remodeling, 2018-2026, (In $ Ten Thousand)
Figure 72 Porter’s Five Force Model
Figure 73 Asia Pacific Epigenomic Market, Country Outlook, 2018-2026, (In $ Ten Thousand)
Figure 74 China Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 75 Japan Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 76 India Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 77 South Korea Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 78 Rest Of Asia Pacific Epigenomic Market, 2018-2026 (In $ Ten Thousand)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report